Vaccinex announced that Dr. Valerie Iddison has joined the company as Chief Medical Officer and a member of the company's Executive Team. Dr. Iddison will provide medical guidance, strategic leadership and oversight of Vaccinex's clinical development programs, including selection of target indications, protocol design and design of clinical monitoring end-points. Since 2008 she has been a member of the Executive team at Bristol-Myers Squibb (BMS), most recently in the position of Executive Director, Global Medical Affairs, Oncology.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.41 USD | -10.63% | +28.20% | -31.13% |
16/05 | Earnings Flash (VCNX) VACCINEX Reports Q1 Revenue $104,000 | MT |
12/04 | Vaccinex, Inc. announced that it has received $1.75 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
-31.13% | 10.16M | |
+18.72% | 125B | |
+14.53% | 109B | |
-2.88% | 24.74B | |
+2.18% | 22.67B | |
-10.09% | 18.14B | |
-41.04% | 16.67B | |
-11.83% | 16.64B | |
+1.46% | 13.45B | |
+24.22% | 11.32B |
- Stock Market
- Equities
- VCNX Stock
- News Vaccinex, Inc.
- Vaccinex Appoints Valerie Iddison as Chief Medical Officer and Member of the Company’s Executive Team